Showing 251-260 of 3158 results for "".
Marketing trends in 2020 – Dermatology gets more social
https://practicaldermatology.com/topics/practice-management/marketing-trends-in-2020-dermatology-gets-more-social/19712/Social media is the place to be for dermatology practices in the New Year. Check out these tips from Ekwa Marketing (www.ekwa.com) to help you build your following, and your patient base.Education is Essential
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/education-is-essential/19680/How do you integrate aesthetics into a new practice, and how do you get patients to understand the basics of skincare? Heidi Prather, MD says that education of both staff and patients is key.DermWireTV: AbbVie to Acquire Allergan, Duobrii Launches, SDPA at 25
https://practicaldermatology.com/topics/psoriasis/dermwiretv-abbvie-to-acquire-allergan-duobrii-launches-sdpa-at-25/19629/In a deal with an equity value of approximately $63 billion, AbbVie has agreed to acquire Allergan. The new company is positioned for new growth platforms and a diversified revenue base; the deal will be immediately accretive to earnings per share, AbbVie says. The Society of Dermatology Physician APrivate Equity in Dermatology: An Inside View
https://practicaldermatology.com/topics/practice-management/private-equity-in-dermatology-an-inside-view/18219/Private equity firms are turning their attention to the dermatology specialty. Why? How has the market changed and what may be on the horizon? An investment banker with knowledge of the field weighs in with an overview from him perspective.The Viability of Phototherapy
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/the-viability-of-phototherapy/18373/The excellent safety profile of phototherapy makes it a viable treatment option for many patients with psoriasis, even in an age of biologics, says Elma Baron, MD. Efficacy of phototherapy is high, she says.Differin Goes OTC, ISDIN Comes to America, Understand AD
https://practicaldermatology.com/topics/psoriasis/dermwiretv-differin-goes-otc-isdin-comes-to-america-understand-ad/18762/Barcelona-based ISDIN is officially operating in the US. The company—which operates in Europe, Latin America, and Asia—is bringing its skincare products to the US market. Regeneron Pharmaceuticals, Sanofi Genzyme, the National Eczema Association, and the Dermatology Nurses Association launch UnderJUVEDERM Voluma Mid-Cheek Injection Demo Video
https://practicaldermatology.com/topics/general-topics/juvederm-voluma-mid-cheek-injection-demo-video/18872/Watch Dr Sheila Barbarino perform a pain free cheek injection using Juvederm Voluma at her Hermosa Beach plastic surgery center, Barbarino Surgical Arts. Juvederm Voluma is the latest of the Juvederm range of hyaluronic acid fillers specifically designed to restore volume in areas of volume loss. VoJulie Woodward: "If I could…"
https://practicaldermatology.com/topics/practice-management/julie-woodward-if-i-could-/19052/A well known oculoplastic surgeon, Julie Woodward, MD explains what device would complement the laser and energy-based device systems she already has in her busy practice. See which device she's pick.We Are All From Somewhere
https://practicaldermatology.com/issues/july-2025/we-are-all-from-somewhere/36504/Everyone in dermatology has a story about where it all started and where choices were made to lead to the next steps. The common themes are baby steps, gratitude, and not closing the door behind them.Approaches to Treating Mild, Moderate, and Severe Cases of Atopic Dermatitis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37161/Practical Dermatology Editorial Board member Peter Lio, MD, a Clinical Assistant Professor of Dermatology and Pediatrics at Northwestern University Feinberg School of Medicine, discusses how atopic dermatitis treatment approaches should differ based on whether the condition is mild, moderate, or sev